Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-02-20Clinical Trial Update: Erythropoietin for Management of Anemia Caused by Chemotherapy [Phase 2]
Phase 2 trial update on erythropoietin for managing anemia caused by chemotherapy in patients with diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-02-19Clinical Trial Update: ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating an ADAM17 inhibitor in combination with Rituximab after autologous stem cell transplant in d…
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL [Phase 2]
Phase 2 open-label clinical trial assessing lenalidomide with MOR00208 in diffuse large B-cell lymphoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-01-10Clinical Trial Update: Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
Clinical trial update for LR-ESHAP in Diffuse Large B-cell Lymphoma (Phase 1/Phase 2) completed.
-
CLINICAL_TRIALS trial_result · 2020-01-09Clinical Trial Update: A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 3]
A Phase 3 trial comparing JHL1101 to rituximab in previously untreated diffuse large B-cell lymphoma was terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-01-03Clinical Trial Update: Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL [Phase 1, Phase 2]
Phase 1/2 trial evaluating VSLI plus rituximab in relapsed/refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mant…
-
CLINICAL_TRIALS trial_result · 2019-12-13Clinical Trial Update: R-CHOP + GM-CSF for Previously Untreated LCL in Elderly [Phase 2]
Phase 2 trial of R-CHOP plus GM-CSF for elderly patients with previously untreated diffuse large B-cell lymphoma has been completed.
-
CLINICAL_TRIALS trial_result · 2019-12-13Clinical Trial Update: Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype [Phase 1, Phase 2]
Phase 1/2 study evaluating lenalidomide with vorinostat, gemcitabine, busulfan, and melphalan with autologous stem-cell transplantation in d…
-
CLINICAL_TRIALS trial_result · 2019-12-11Clinical Trial Update: Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. [Phase 2]
Phase 2 trial evaluating sintilimab plus R-CHOP as first-line treatment for diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]
Phase 2 clinical trial assessing donor atorvastatin to prevent severe acute GVHD after nonmyeloablative peripheral blood stem cell transplan…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT [Phase 2]
Phase 2 trial evaluating oral panobinostat in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), either after st…
-
CLINICAL_TRIALS trial_result · 2019-11-05Clinical Trial Update: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and efficacy of obinutuzumab, polatuzumab vedotin, and atezolizumab in relapsed/refractory follicular lymph…
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma [Phase 3]
Phase 3 trial comparing RTXM83 plus CHOP to Rituximab plus CHOP in diffuse large B-cell lymphoma has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) [Phase 2]
Phase II study comparing LR-GEM to R-GEM-P in second-line treatment of diffuse large B-cell lymphoma is ongoing/unknown status.
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients [Phase 1, Phase 2]
Phase 1/2 study evaluating brentuximab vedotin with chemotherapy in CD30+ primary mediastinal large B-cell lymphoma, CD30+ diffuse large B-c…
-
CLINICAL_TRIALS trial_result · 2019-09-16Clinical Trial Update: A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating durvalumab with R-CHOP or lenalidomide plus R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma [Phase 3]
A Phase 3 randomized trial comparing R-ICE versus R-DHAP in adults 18-65 with relapsed diffuse large B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-08-26Clinical Trial Update: Mini-CHOP and Rituximab in Patients Aged Over 80 Years [Phase 2]
Phase 2 trial update on Mini-CHOP plus Rituximab in patients over 80 with diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2019-08-07Clinical Trial Update: Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for patients with primary breast diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL [Phase 2]
Phase 2 clinical trial update for GVD±R regimen in ASCT-eligible patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL).
-
CLINICAL_TRIALS trial_result · 2019-07-25Clinical Trial Update: Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma [Phase 4]
Phase 4 trial update of apatinib for relapsed and refractory diffuse large B-cell lymphoma has been completed.
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) [Phase 1]
Phase 1 dose-exploration trial of Birabresib (MK-8628) in selected hematologic malignancies (AML variants and DLBCL) has been terminated wit…
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma [Phase 1]
Phase 1 study of GSK2816126 in relapsed/refractory B-cell and solid tumor malignancies terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-27Clinical Trial Update: A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas [Phase 1, Phase 2]
A multi-center phase 1/2 trial evaluating ibrutinib combined with MEDI4736 in relapsed or refractory lymphomas has completed enrollment with…
-
CLINICAL_TRIALS trial_result · 2019-06-17Clinical Trial Update: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL [Phase 2]
Phase 2 trial comparing BI 836826-GemOx vs R-GemOx in relapsed/refractory diffuse large B-cell lymphoma to determine dose and efficacy; stud…